Tvardi director granted 6,000 stock options

Tvardi Therapeutics, Inc. director Cynthia Smith reported receiving a grant of stock options as equity compensation.

Rhea-AI Filing Summary

Tvardi Therapeutics, Inc. director Cynthia Smith reported receiving a grant of stock options as equity compensation. The award covers 6,000 options to buy Tvardi common stock at an exercise price of $2.78 per share, expiring on June 8, 2036.

All 6,000 underlying shares vest in a single tranche on the earlier of June 9, 2027 or the date of Tvardi’s next annual meeting of stockholders, provided she remains in continuous service through that vesting date. Following this grant, she holds 6,000 derivative securities directly.

Insider Trade Summary

Grant/Award: 6,000 shares

Grant/Award 1 txn

Insider Smith Cynthia

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	6,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 6,000 contracts (Direct)

Footnotes (1)

1. F1. 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

Key Figures

Options granted: 6,000 options Exercise price: $2.78 per share Expiration date: June 8, 2036 +2 more

5 metrics

Options granted 6,000 options Stock Option grant to director Cynthia Smith

Exercise price $2.78 per share Exercise price for 6,000 stock options

Expiration date June 8, 2036 Option grant expiration date

Vesting trigger date June 9, 2027 Earlier of this date or next annual meeting, subject to service

Shares underlying options 6,000 shares Underlying Tvardi common stock for this option grant

Key Terms

Stock Option (right to buy), Common Stock, Grant, award, or other acquisition, exercise price, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

exercise price financial

"conversion_or_exercise_price: 2.7800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

continuous service financial

"subject to the Reporting Person's continuous service through such vesting date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Tvardi Therapeutics (TVRD) director Cynthia Smith report?

Cynthia Smith reported receiving a grant of stock options for 6,000 shares of Tvardi Therapeutics common stock. These options are a compensation award, not an open-market stock purchase or sale, and are exercisable at a fixed price if they vest.

How many Tvardi Therapeutics (TVRD) options did Cynthia Smith receive and at what price?

She received 6,000 stock options with an exercise price of $2.78 per share. This means she can buy up to 6,000 Tvardi common shares at $2.78 if the options vest and she chooses to exercise them before expiration.

When do Cynthia Smith’s Tvardi Therapeutics (TVRD) options vest?

All 6,000 options vest 100% on the earlier of June 9, 2027 or Tvardi’s next annual meeting of stockholders. Vesting is conditioned on her continuous service with the company through the applicable vesting date, according to the filing footnote.

When do Cynthia Smith’s Tvardi Therapeutics (TVRD) stock options expire?

The options expire on June 8, 2036 if not exercised earlier. After the expiration date, she would no longer have the right to purchase Tvardi common stock under this particular 6,000-share option grant at the fixed $2.78 exercise price.

Does Cynthia Smith’s Tvardi Therapeutics (TVRD) Form 4 show any stock sales or purchases?

The Form 4 reports only a grant of 6,000 stock options as a compensation award. It does not show any open-market purchases or sales of Tvardi common stock, and the transaction code indicates a grant or other acquisition of a derivative security.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 04:30 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Smith Cynthia

(Last) (First) (Middle)

C/O TVARDI THERAPEUTICS, INC.

3 SUGAR CREEK CTR BLVD, STE 525

(Street)

SUGAR LAND TEXAS 77478

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tvardi Therapeutics, Inc. [ TVRD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$2.78	06/09/2026		A		6,000		(1)	06/08/2036	Common Stock	6,000	$0	6,000	D

Explanation of Responses:

1. 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Dan Conn, Attorney-in-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)